

# In vitro Removal of Therapeutic Drugs with a Novel Adsorbent System

Karl Reiter<sup>a,b</sup> Valeria Bordoni<sup>b</sup> Giuliano Dall'Olio<sup>c</sup> Maria Grazia Ricatti<sup>d</sup>  
Maurizio Soli<sup>e</sup> Salvatore Ruperti<sup>d</sup> Giuliano Soffiati<sup>c</sup> Elisabetta Galloni<sup>b</sup>  
Vincenzo D'Intini<sup>b</sup> Rinaldo Bellomo<sup>f</sup> Claudio Ronco<sup>b</sup>

<sup>a</sup>University Children's Hospital, Kinderklinik und Kinderpoliklinik am Dr. von Haunerschen Kinderspital, Munich, Germany; Departments of <sup>b</sup>Nephrology, <sup>c</sup>Clinical Chemistry, <sup>d</sup>Pharmacy, and <sup>e</sup>Immunohematology, Ospedale San Bortolo, Vicenza, Italy; <sup>f</sup>Austin and Repatriation Medical Centre, Heidelberg, Vic., Australia

## Key Words

Sorbents · Hemoperfusion · Intoxication · Detoxification · Drugs, intoxication · Middle molecular weight molecules

## Abstract

**Background/Aim:** Substances in the middle molecular weight range have been shown to play a significant pathogenetic role in as diverse disorders as end-stage renal disease and multiple organ failure. To overcome the limitations in the amount removed by hemofilters, new sorbents with a high biocompatibility are actively being developed. Furthermore, biocompatible sorbents by their nonspecific adsorptive behavior could have great impact on detoxification treatment in exogenous intoxications. We performed an in vitro evaluation of a newly developed highly biocompatible sorbent cartridge (Betisorb<sup>®</sup>), examining its adsorptive capacity concerning therapeutic drugs. **Methods:** Uremic blood spiked with a range of therapeutic drugs was recirculated for 2 h in an in vitro hemoperfusion circuit containing a Betisorb device for hemoperfusion. The drug concentrations before and after the passage of the cartridge were measured, and the total amount removed was calculated. **Results:** The sorbent showed effective removal of glyco-

peptide antibiotics, digoxin, theophylline, phenobarbital, phenytoin, carbamazepine, and valproic acid. Moderate removal could be demonstrated for tacrolimus and cyclosporine A; aminoglycosides were removed to a small extent only. **Conclusions:** Betisorb hemoperfusion shows a potent adsorptive capacity concerning therapeutic drugs (except aminoglycosides) and could be of major value in the treatment of intoxications. On the other hand, drug monitoring and possible adjustments are necessary during Betisorb hemoperfusion to maintain the therapeutic ranges of the drugs in blood.

Copyright © 2002 S. Karger AG, Basel

## Introduction

In chronic hemodialysis, much effort is invested in improving the long-term morbidity by removal of toxic substances in the middle molecular weight range (e.g.,  $\beta$ -microglobulin). These molecules accumulate in chronic renal failure and are not sufficiently removed by conventional hemodialyzers, either by using diffusion or convection [1]. Therefore, increasingly sophisticated techniques for blood purification utilizing high convective rates and/or adsorption mechanisms are being developed to expand

## KARGER

Fax + 41 61 306 12 34  
E-Mail [karger@karger.ch](mailto:karger@karger.ch)  
[www.karger.com](http://www.karger.com)

© 2002 S. Karger AG, Basel  
0253-5068/02/0204-0380\$18.50/0

Accessible online at:  
[www.karger.com/journals/bpu](http://www.karger.com/journals/bpu)

Dr. Claudio Ronco  
Department of Nephrology, Ospedale San Bortolo  
I-36100 Vicenza (Italy)  
Tel. +39 0444 993 869, Fax +39 0444 993 949  
E-Mail [cronco@goldnet.it](mailto:cronco@goldnet.it)

the range of substances removed by renal replacement techniques.

In the intensive care environment renal replacement therapy is a well-established treatment modality for acute renal failure. Renal failure is frequently seen in multiple organ failure syndrome caused by the systemic inflammatory response syndrome. Cytokines acting as protagonists in this syndrome have molecular weights in the middle-molecular weight range. A growing body of evidence suggests a possible beneficial role of removal of middle molecular weight substances in addition to uremic toxins in the septic syndrome [2].

Finally, further refinement of blood purification techniques relying on sorbent devices could conceivably have a major impact on detoxification therapy in exogenous intoxications (including poisons and drugs). Hemoperfusion techniques using charcoal cartridges are used in only very selected cases, mostly because of cost and poor hemocompatibility of the sorbent material, leading to platelet drop and leukopenia [3]. Increasing charcoal biocompatibility by coating leads to a significant loss of adsorbing capacity, rendering charcoal hemoperfusion a modality of limited usefulness. Through the availability of new synthetic polymers with remarkable adsorption capacity in addition to excellent biocompatibility, the role of hemoperfusion in the treatment of intoxications possibly will have to be revised. Nevertheless, since adsorption is not selective with resins and other sorbents, unwanted losses of beneficial substances or active drugs may occur during treatment. In this view, it is essential to define the characteristics of a given sorbent in terms of the adsorption capacity for drugs. This approach will define the possible indications in the case of intoxication and overdose, but also the required prescriptive adjustments in the case of a renal replacement treatment carried out with the sorbent.

We studied a new hemoperfusion cartridge (Betisorb®; Renal Tech) which has been designed for high-efficiency removal of substances in the middle molecular weight range like  $\beta_2$ -microglobulin [4] and cytokines [5]. Due to the unpredictable nature of adsorption, we expected this sorbent device to have a high removal capability concerning drugs. Excellent hemocompatibility of the Betisorb cartridge has been shown in earlier studies [6].

The aim of this in vitro-study was to evaluate the adsorption capacity in whole blood for several commonly employed drugs. This serves the purpose of providing pharmacokinetic data as part of the preclinical evaluation as well as delineating a possible role for the cartridge in intoxication treatment.

## Materials and Methods

### *Experimental Setup*

The investigation was performed within a set of experiments examining the adsorptive capacity of drugs by the Betisorb device applied to uremic blood. Uremic blood was produced in vitro by mixing concentrated ultrafiltrate from a chronic dialysis patient with erythrocyte concentrates donated by healthy volunteers. The experiment was performed twice in an identical fashion, but using ultrafiltrate of 2 different patients.

About 40 liters of ultrafiltrate derived from one hemofiltration session was used. Subsequently, this amount was recirculated in an in vitro circuit utilizing a low-flux polysulfone hemofilter (Fresenius F8, FMC) until about 1,200 ml concentrated fluid was obtained. Assuming a sieving coefficient of 0.5 of the hemofiltration membrane used in the patient and a sieving coefficient of 0.05 of the low-flux hemofilter, the final product was expected to be isotonic to plasma water but containing middle molecules at a concentration similar to that of the uremic plasma at the beginning of a hemodialysis session. We confirmed this in a previous experiment [6]. Then a portion of ultrafiltrate was mixed with two bags of concentrated erythrocytes to obtain a whole amount of reconstituted blood of 1,200 ml with a hematocrit of about 30%. This amount was divided into two aliquots of 600 ml each, to which the drugs to be studied were added immediately before the experiment (fig. 1).


The blood was circulated in an in vitro hemoperfusion circuit for 120 min at a set flow rate of 250 ml/min on a hemodialyzer machine. Adequate mixing in the blood reservoir was ensured by careful positioning of arterial and venous lines. Pre- and postcartridge pressures were measured continuously (fig. 2). A 100-gram Betisorb pilot cartridge was used for the experiments.

Blood samples for determination of drug levels were drawn at the sampling ports placed before and after the cartridge at 0, 5, 15, 30, 60, 90, and 120 min from the start of the experiment.


Instantaneous removal was measured by the arteriovenous difference multiplied by the flow; cumulative removal was calculated by the reservoir concentration of the specific drug at the beginning and at the end of the experiment corrected by variations in the reservoir volume due to blood samples. Progressive changes in the reservoir concentration were monitored by the concentration in the arterial line at different times of the experiments. Each experiment was performed twice except for tacrolimus.

### *Laboratory Methods*

The drug levels were determined by the following methods: carbamazepine, phenytoin, phenobarbital, and theophylline by particle-enhanced turbidimetric inhibition immunoassay (instrument Dimension RxL; Dade-Behring); digoxin and cyclosporine A by immunoassay (instrument Dimension RxL; Dade-Behring); valproic acid by enzyme-monitored immunoassay (instrument ACA; Dade-Behring); amikacin, gentamicin, netilmicin, teicoplanin, tobramycin, and vancomycin by fluorescence polarization immunoassay (instrument TDx; Abbott), and tacrolimus by microparticle enzyme immunoassay (instrument Imx; Abbott). The formulas used for calculations of the kinetic parameters are given in the appendix.



1



2

Fig. 1. The process of obtaining uremic blood starts from concentrated ultrafiltrate obtained from patients undergoing hemofiltration and normal red cells. The mixture simulates the composition of uremic blood. The batch is then split into two aliquots that are injected with the drugs studied.

Fig. 2. Schematic representation of the in vitro circuit utilized for the study. P = Pump; S1 and S2 = sampling ports.

Table 1. Time course of plasma levels according to sampling site

Time min	Amikacin µg/ml				Gentamicin µg/ml				Tobramycin µg/ml				Netilmicin µg/ml			
	experiment I		experiment II		experiment I		experiment II		experiment I		experiment II		experiment I		experiment II	
	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site
a																
0	520		97		153		26.2		135		21.6		180		24.3	
15	493	472	85	83	138	127	19.1	18.7	125	117	16.7	16.4	149	138	15.6	15.3
30	497	478	84	85	138	121	18.6	18.4	117	108	16.9	16.5	146	144	15.2	15.5
60	493	472	84	85	136	132	17.6	17.6	113	113	17.6	17.1	146	142	14.7	15
120	496	473	83	84	129	128	17.0	16.8	111	119	17.4	17.8	147	149	13.8	14
Time min	Vancomycin µg/ml				Teicoplanin µg/ml				Digoxin ng/ml							
	experiment I		experiment II		experiment I		experiment II		experiment I		experiment II					
	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site				
b																
0	1,048		221		179		165		3,900		6,8					
15	474	414	42.7	35.8	78	66	25	6.5	358	86	2.4	1.4				
30	350	314	15.8	8.9	59	55	2.6	0.7	90	52	0.8	0.5				
60	218	205	<0.01	<0.01	36	29	<0.01	<0.01	29	22	0.2	0.1				
120	137	148	<0.01	<0.01	19	21	<0.01	<0.01	16	13	<0.05	<0.05				
Time min	Cyclosporine ng/ml				Theophylline µg/ml				Tacrolimus ng/ml							
	experiment I		experiment II		experiment I		experiment II		experiment I		experiment II					
	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site				
c																
0	396		604		32.4		34.4		84.3							
15	338	312	380	386	10.2	9.0	12.0	10.6	21.5	21						
30	310	277	347	340	9.8	9.6	9.7	9.6	21.4	19.5						
60	318	291	369	362	9.7	9.5	8.5	8.2	20.8	20						
120	233	217	306	315	9.4	9.2	8.9	8.6	18.6	21.1						
Time min	Valproic acid µg/ml				Phenobarbital µg/ml				Carbamazepine µg/ml				Phenytoin µg/ml			
	experiment I		experiment II		experiment I		experiment II		experiment I		experiment II		experiment I		experiment II	
	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site	arterial site	venous site
d																
0	105.7		123.7		27.7		61.4		9.6		12.3		16.3		23.3	
15	33.1	24.4	45.3	38.7	2.5	1.3	9.9	7.7	0.5	<0.5	1.4	0.6	1.8	1	3.5	2.4
30	25.2	23	36.9	34	1.3	0.8	4.4	4.1	<0.5	<0.5	0.8	0.6	0.9	0.9	1.7	1.2
60	21.2	28.4	28.6	29.8	1.2	0.6	4	3.4	<0.5	<0.5	<0.5	<0.5	<0.5	<0.5	<0.5	<0.5
120	20.6	17.3	26.7	27.6	0.5	0.5	2.3	2	<0.5	<0.5	<0.5	<0.5	<0.5	<0.5	<0.5	<0.5

## Results

All experiments were performed without major interruptions or technical problems. In detail, the end-to-end pressure drop in the cartridge remained stable over time,

indicating a constant patency of the unit and the absence of major changes in the priming volume of the sorbent cartridge (fig. 3). The data are reported in table 1. The respective drug concentrations are listed with regard to the relative time points of sampling and sampling site (ar-

terial or venous, i.e., before or after the hemoperfusion cartridge). During the experiment, the blood pH value remained stable at 6.8. The cartridge performed very well with respect to hemocompatibility (table 2), showing no changes in platelet and leukocyte counts. As depicted in




Fig. 3. Pressure behaviours at the inlet and outlet of the cartridge during the study. The constant value indicates that no clotting or loss of surface area occurred during the study.

figures 4 and 5, there were no visible signs of blood stasis during and at the end of the hemoperfusion session as well as after rinsing the cartridge with saline.

Aminoglycosides were removed to a marginal degree. Figure 6 shows the percentages by which the plasma levels declined over time, the arterial value at time point zero being set at 100%. The plasma levels of amikacin decreased by 4.6 and 14.4%. Practically all removal took place within the first 15 min. Over the following 90 min, adsorption and desorption from the membrane seemed to be in equilibrium, as a reduction in plasma levels by passage over the cartridge still was measurable at specific time points, but not overall.

Netilmicin, tobramycin, and gentamicin (fig. 6, 7) showed a similar behavior, with maximal removal also within the first 15 min. With lower initial plasma drug levels, the relative amount of removal was higher (up to 42% with netilmicin). Therefore, the relative removal rates generally were larger in the second set of experiments, where the initial drug concentrations were lower because of comparable absolute amounts of removal.

Vancomycin, teicoplanin, digoxin, carbamazepine, phenytoin, and phenobarbital were practically completely




Fig. 4. Pictures of the cartridge at different times during the study. It is evident that a homogeneous distribution of blood is present for the entire duration of the experiment.

Table 2. Hemocompatibility: standard blood values at start and end of the experiments

Time min	RBC $10^6/\text{mm}^3$		Hct, %		WBC $10^3/\text{mm}^3$		Platelets G/l		Albumin, g/l	
	exp I	exp II	exp I	exp II	exp I	exp II	exp I	exp II	exp I	exp II
0	2.74	3.56	25.9	32.3	1.22	1.02	34	7	0.4	0.8
120	2.71	3.27	25.7	29.6	1.04	0.51	24	1	0.2	0.5




Fig. 6. Percent decrease in blood concentration of gentamicin and amikacin over time.




Fig. 7. Percent decrease in blood concentration of netilmicin and tobramycin over time.




Fig. 5. Pictures of the cartridge after the experiment. The sorbent appears clean and well rinsed confirming the absence of blood residuals.

removed, predominantly within 5–15 min (fig. 8, 9). Slight but insignificant amounts of desorption were apparent only with vancomycin between time points 60 and 120 min (the values after the filter passage being slightly higher than those before). Theophylline, tacrolimus (fig. 10), and valproic acid (fig. 9) were significantly adsorbed to an extent of 72–84%. Tacrolimus and valproic acid showed minimal desorption after 60 min. Cyclosporine (fig. 10) showed intermediate removal amounts of 45 and 48%. In the first experiment, there was ongoing adsorption of cyclosporine over 120 min, whereas in the second set a slight desorption could be demonstrated after 60 min. The cumulative removal for all drugs examined is shown in table 3.

### Discussion

Chronic hemodialysis patients continue to have a significant morbidity despite considerable improvement in filter and dialysis techniques with high-efficiency removal of low molecular weight uremic toxins [1]. Over the last years more and more (definitive and probable) uremic toxins in the middle molecular weight range have been identified. A search for means to effectively remove these toxins has been launched. As sorbent materials with a much higher biocompatibility as compared with charcoal have become available, a renewed interest in blood purification modalities using sorbents has developed [6]. Apart from employment in chronic hemodialysis, a further ex-




Fig. 8. Percent decrease in blood concentration of vancomycin, teicoplanin and digoxin over time.




Fig. 9. Percent decrease in blood concentration of phenobarbital, phenytoin, carbamazepine and vaproic acid over time.




Fig. 10. Percent decrease in blood concentration of theophylline, tacrolimus and cyclosporine over time.

citing indication for sorbent hemoperfusion undergoing active investigation is in patients with systemic inflammatory response syndrome for mediator removal, e.g., cytokines [2]. Furthermore, a number of currently used drugs may sometimes be observed at toxic concentrations (e.g., theophylline, digoxin, and valproic acid) due to accidental overdose or to other conditions. These are major

challenges for detoxification therapies, as protein binding and/or hydrophobicity of the molecules often preclude effective removal by forced diuresis or hemofiltration/dialysis modalities. In severe intoxications charcoal hemoperfusion has been a historical standard treatment. However, its application has been limited by low biocompatibility (when uncoated) or less-than-optimal adsorptive capacity (when made more biocompatible by coating). Adsorbents of any type – excluding antibody-coated membranes for immune system specific removal – characteristically behave nonspecifically in their adsorptive process. Therefore, studies are important to evaluate the impact of their use on the plasma levels of therapeutic drugs either for detoxification purposes or for optimization of drug prescription.

In this study, we evaluated the performance of the hemoperfusion cartridge Betasorb. This device is a specifically developed adsorption column for removal of  $\beta_2$ -microglobulin (11.8 kD). It contains hydrated, hypercross-linked polystyrene resin beads (designed to remove molecules between 4 and 20 kD; bead size 400–1,000  $\mu\text{m}$ ) with an enhanced proportion of mesopores in the range of 2–20 nm. The cartridge shows an excellent hemocompatibility [6, 7] through coating by hydrophilic substitution of vinyl chains [8]. The flow-dynamic pattern has been characterized in vitro [9]. With ex vivo-testing in whole blood, the plasma levels of  $\beta_2$ -microglobulin, tumor necrosis factor alpha, and interleukin 1 beta could be significantly reduced [5, 7]. In dogs with chronic renal failure, the plas-

Table 3. Total mass removal over 120 min

	Total amount	
	at start	removed
Amikacin, mg	624	128
Gentamicin, mg	183.6	54.6
Tobramycin, mg	162	51
Netilmicin, mg	216	69
Vancomycin, mg	1,258	1,121
Teicoplanin, mg	198	198
Digoxin, $\mu$ g	4,680	4,664
Cyclosporine, $\mu$ g	725	434
Theophylline, mg	412.8	32.8
Tacrolimus, $\mu$ g	101.2	83.5
Valproic acid, mg	148	123
Phenobarbital, mg	73.6	71.5
Carbamazepine, mg	14.8	14.8
Phenytoin, mg	28	28

ma  $\beta_2$ -microglobulin levels were reduced in excess of 70% per session of combined hemodialysis and Betasorb hemoperfusion [4]. First clinical experience demonstrated a decrease in the plasma concentrations of  $\beta_2$ -microglobulin by 79 and 69% [10, 11].

We now have characterized the adsorptive performance of this device with regard to 14 commonly used drugs. The drugs examined differ in molecular weight (range 236–1,993 Da), protein binding (range 0–95%), as well as solubility (very water soluble to insoluble). As the blood preparation examined contained a high number of drugs, possible chemical interactions could be of concern. To our knowledge, no such interactions in whole blood have been described for the drugs we used in our experiments.

The different drugs studied encompass a wide range of medications commonly prescribed in internal medicine and the intensive care setting. They are potent drugs; consequently, their plasma levels often need to be kept in a narrow therapeutic range. Therefore, it is vital to know to what extent plasma levels are influenced by hemoperfusion. On the one hand, hemoperfusion performed for a reason not related to drug intoxication could lead to dangerous lowering of the plasma levels of the drug. On the other hand, obviously a high absorptive capacity for toxic drugs would open a wide avenue for therapeutic use in detoxification.

All aminoglycosides tested in our study were poorly adsorbed. The use of the Betasorb device probably should be of no significance concerning their dosage. The other

drugs studied were removed to a significant degree. Hence, additional dosages may be necessary to be given and strict serum drug level monitoring performed when using the Betasorb device.

Concerning intoxications with digoxin, carbamazepine, teicoplanin, vancomycin, valproic acid, phenytoin, phenobarbital, and theophylline, Betasorb hemoperfusion demonstrates a potentially important role in detoxification. Important to note is the possibility of later desorption of the drug from the membrane. It would seem prudent to limit hemoperfusion in drug intoxication to a period of 1 h or to increase the size of the cartridge employed for this purpose. In interpreting these results, it should be kept in mind that only a prototype device containing 100 g sorbent was used. For clinical implementation, the amount of sorbent per cartridge will certainly be increased by the manufacturer.

Desorption from the membrane after establishment of a concentration, equilibrium with plasma is a known process which depends on the physicochemical characteristics of the adsorption. Potentially relevant desorption should be detectable by a pre-post cartridge gradient with a higher drug concentration after passage of the filter. This was the case, to a minimal extent, for valproic acid, teicoplanin, vancomycin, netilmicin, and tobramycin without clinically significant impact on the plasma levels. Nevertheless, with very high plasma drug levels as encountered in intoxications, desorption should be a function of absolute adsorbing capacity of the cartridge. The possibility that desorption then takes place at higher plasma levels cannot be excluded by our data.

Tacrolimus is known to accumulate in erythrocytes, and equilibrium dynamics over the erythrocyte membrane have to be considered. The same is valid for cyclosporine. In our study, both drugs showed the lowest removal rates by Betasorb as compared with other drugs. Slow transport across the erythrocyte membrane may be the cause. On the other hand, we could demonstrate a slight desorption starting after 60 min of perfusion which argues for saturation of the cartridge with only moderately strong affinity as the underlying mechanism. For clarifying this issue, further investigations including a prolonged perfusion time have to be conducted.

Our results compare favorably with sorbent devices in use up to now, like charcoal [3] and Amberlite resins [13]. Notably, the Betasorb cartridge, as compared with older sorbents, has a superior biocompatibility [14]. Of the more recently developed sorbent devices [reviewed in 15], only the microsphere detoxification system has undergone in vitro testing with respect to drugs. Only data on



phenobarbital removal are available, showing significant effects [16].

In conclusion, in this study, we investigated in an *in vitro* hemoperfusion circuit the drug-adsorbing capacity of the new synthetic sorbent device Betasorb. The removal kinetics are also described. Excluding aminoglycosides, we could demonstrate an impressive removal of a number of therapeutic drugs relevant in current medical and intensive care practice. The data are relevant for drug dosing during hemoperfusion. Modern sorbent technology due to its excellent biocompatibility and high adsorbent capacity has the potential to become the first-line treatment modality in a number of severe intoxications by medical drugs.

## References

- Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJ, Agoda LY, Port FK: Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. *Am J Kidney Dis* 1999;33:349–355.
- Ronco C, Brendolan A, Dan M, Piccinni P, Bellomo R, Wratten ML, Inguaggiato P, Tetta C: Use of sorbents in acute renal failure and sepsis; in Ronco C, Winchester JF (eds): *Dialysis, Dialyzers and Sorbents*. Contrib Nephrol. Basel, Karger, 2001, vol 133, pp 180–193.
- Winchester JF: Use of dialysis and hemoperfusion in treatment of poisoning; in Daugirdas JT, Ing TS (eds): *Handbook of Dialysis*, ed 2. Boston, Little, Brown, 1994.
- Brady JA: Beta-2-microglobulin removal in the uremic canine with combined hemodialysis/hemoperfusion using a new adsorbent device (abstract). *J Am Soc Nephrol* 2000;11:2954.
- Brady JA: Ex vivo cytokine clearance with a new adsorbent material from endotoxin-stimulated whole blood (abstract). *J Am Soc Nephrol* 2000;11:3092.
- Bosch T, Wendler T, Duhr C, Brady J, Samtleben W: Ex-vivo biocompatibility of a new beta-2-microglobulin adsorbent during hemoperfusion with human whole blood (abstract). *J Am Soc Nephrol* 2000;11:257.
- La Greca G, Brendolan A, Ghezzi PM, De Smet R, Tetta C, Gervasio R, Ronco C: The concept of sorbent in hemodialysis. *Int J Artif Organs* 1998;21:303–308.
- Brady JA: Ex vivo performance of a new beta-2-microglobulin adsorbent material (abstract). *J Am Soc Nephrol* 2000;11:2953.
- Davankov V, Pavlova L, Tsyurupa M, Brady J, Balsamo M, Yousha E: Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure. *J Chromatogr B* 2000;739:73–80.
- Polaschegg HD, Ronco C, Soli M: Characterization of flow-dynamic pattern in a new sorbent cartridge for combined hemoperfusion-hemodialysis; in Ronco C, Winchester JF (eds): *Dialysis, Dialyzers and Sorbents*. Contrib Nephrol. Basel, Karger, 2001, vol 133, pp 154–165.
- Ronco C, Brendolan A, Winchester JF, Golds E, Clemmer J, Polaschegg HD, Muller TE, Davankov V, Tsyurupa M, Pavlova L, Pavlov M, La Greca G, Levin NW: First clinical experience with an adjunctive hemoperfusion device designed specifically to remove beta-2-microglobulin in hemodialysis; in Ronco C, Winchester JF (eds): *Dialysis, Dialyzers and Sorbents*. Contrib Nephrol. Basel, Karger, 2001, vol 133, pp 166–173.
- Reiter K, Bordoni V, Soffiati G, Fortunato L, Soli M, Galloni E, Winchester JF, Ronco C: *In vitro* removal of hormones by the Betasorb hemoperfusion cartridge, in press.
- Raja RM: Resin hemoperfusion for drug intoxication – an update. *Int J Artif Organs* 1986;9:319–322.
- Stein G, Sperschneider H, Borner A, Stelzner A, Gunther K, Fünfstück R, Keil E, Lauterbach H: Influence of hemoperfusion with XAD-4 resin on the concentration of biologic constituents in the blood. *Int J Artif Organs* 1982;5:105–109.
- Lameire NH, De Vriese AS: Adsorption techniques and the use of sorbents; in Ronco C, Winchester JF (eds): *Dialysis, Dialyzers and Sorbents*. Contrib Nephrol. Basel, Karger, 2001, vol 133, pp 140–153.
- Weber C, Rajnoch C, Loth F, Schima H, Falkenhagen D: The Microspheres based Detoxification System (MDS): A new extracorporeal blood purification technology based on recirculated microspherical adsorbent particles. *Int J Artif Organs* 1994;17:595–602.

## Appendix

Arterial venous difference ( $\Delta$ )	$\text{Conc}_{\text{art}} - \text{Conc}_{\text{ven}}$
Removal rate	$(\text{Conc}_{\text{art}} - \text{Conc}_{\text{ven}}) \times \text{Qb}$
Cumulative mass removal (at t)	$(\text{Conc}_{\text{res}} \times V)_{\text{base}} - (\text{Conc}_{\text{res}} \times V)_t$
Clearance	$[(\text{Conc}_{\text{art}} - \text{Conc}_{\text{ven}})/\text{Conc}_{\text{art}}] \times \text{Qb}$

where  $\text{Conc}_{\text{art}}$  = concentration of the solute before the cartridge,  $\text{Conc}_{\text{ven}}$  = concentration of the solute after the cartridge,  $\text{Conc}_{\text{res}}$  = concentration of the solute in the reservoir,  $V$  = volume of blood in the reservoir,  $\text{Qb}$  = effective blood flow.